Medivation


Stock Update (NASDAQ:MDVN): Medivation Inc Voted Three Years in a Row Among Top Workplaces in the San Francisco Bay Area

Medivation Inc (NASDAQ:MDVN) announced that for the third year in a row it was named among the top mid-sized companies in the San Francisco …

Company Update (NASDAQ:MDVN): Medivation Inc to Redeem Outstanding Convertible Notes Due 2017

Medivation Inc (NASDAQ:MDVN) announced that it has issued a notice of redemption to redeem on July 24, 2015 all of its outstanding 2.625% Convertible …

Company Update (NASDAQ:MDVN): Medivation Inc and Astellas Announce Enrollment of the First Patients in Advanced Prostate Cancer Outcomes Registry

Medivation Inc (NASDAQ:MDVN) and Astellas announced that the first patients have been enrolled in TRUMPET (Treatment Registry for Outcomes in CRPC Patie nts), a …

Wedbush Weighs in on Medivation Following Phase II TERRAIN Study Results

Medivation (NASDAQ: MDVN) is best known for developing therapies to treat serious diseases. Earlier in 2014 the biopharmaceutical company received FDA approval to expand …

Medivation Reports Third Quarter Financial Results and Provides Corporate Update

(Marketwired) – 11/06/14 – Medivation, Inc. (NASDAQ:MDVN) today reported its financial results for the third quarter ended September 30, 2014.

William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015

2014 has been an eventful year on Wall Street. Now that the year is coming to an end, what stocks should investors be …

Maxim Raises Medivation Price Target Following Solid Quarter Results

Maxim Group analyst Jason Kolbert maintained a Buy rating on Medivation (NASDAQ:MDVN) and slightly raised his price target to $118 (from $112), as …

Brean Capital Raises Medivation Price Target On Higher Revenue Projections

In a research report sent to investors today, Brean Capital analyst Jonathan Aschoff reaffirmed a Buy rating on Medivation (NASDAQ:MDVN) and increased his price …

Ahead Of 3Q14 Earnings We See Medivation Likely Beating The Street, Says Wedbush

In a research report published today, Wedbush analyst David Nierengarten reiterated an Outperfom rating on Medivation (NASDAQ:MDVN) with a $109 price target, ahead of the …

Medivation: Xtandi Has Huge Upside Potential, Says Canaccord

In a research report issued today, Canaccord analyst John Newman upgraded shares of Medivation (NASDAQ:MDVN) to Buy from Hold and doubled his price target to $132 …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts